TY  -  
T1  - Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment 
SN  -  /  
UR  - http://hdl.handle.net/10138/308999 
T3  -  
A1  - Skaga, Erlend; Kulesskiy, Evgeny; Brynjulvsen, Marit; Sandberg, Cecilie J; Potdar, Swapnil; Langmoen, Iver A; Laakso, Aki; Gaál-Paavola, Emília; Perola, Markus; Wennerberg, Krister; Vik-Mo, Einar O 
A2  -  
PB  - Springer Berlin Heidelberg 
Y1  - 2019 
LA  - eng 
AB  - Abstract
              
                Background
                Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for stratified treatments allow clinical decision making in only a small minority of screened patients. Addressing tumor heterogeneity, we aimed to establish a clinical translational protocol in recurrent GBM (recGBM) utilizing autologous gliobla... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Glioblastoma; Recurrent glioblastoma; Glioblastoma stem cells; High-throughput drug screening; Drug sensitivity and resistance testing; Individualized medicine; Drug sensitivity 
N1  -   
PP  -  
ER  -